Advertisement

Search Results

Advertisement



Your search for Kathleen Moore, MD matches 37 pages

Showing 1 - 37


gynecologic cancers

Activity Shown for Antibody-Drug Conjugates in Gynecologic Cancers

The recent approval of mirvetuximab soravtansine-gynx is a testament to the emerging benefit of antibody-drug conjugates in recurrent ovarian cancer. Other agents of this class are now eliciting excitement as they demonstrate high response rates in a population with unmet clinical needs, according...

gynecologic cancers

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

As reported in The New England Journal of Medicine by Kathleen N. Moore, MD, and colleagues, the phase III MIRASOL trial has shown improved progression-free and overall survival with mirvetuximab soravtansine-gynx vs chemotherapy in previously treated patients with folate receptor–alpha...

gynecologic cancers

ARTISTRY-7 and ROSELLA: Phase III Trials to Evaluate Novel Agents in Platinum-Resistant Ovarian Cancer

Platinum resistance occurs in almost all patients whose ovarian cancer recurs. Single-agent chemotherapies are commonly used in this setting, but outcomes are generally poor, leaving a large unmet need for effective treatment. At the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on...

Expert Point of View: Kathleen Moore, MD, MS

“I think the NOW trial is a great study,” said Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Oklahoma City, who shared her thoughts on the trial with The ...

gynecologic cancers

De-escalation of Surgery Feasible for Selected Patients With Low-Risk, Early-Stage Cervical Cancer

Many patients with early-stage, low-risk cervical cancer may be spared the side effects associated with radical hysterectomy and undergo simple hysterectomy with pelvic lymph node dissection instead, according to results of the international phase III SHAPE study presented at the 2023 ASCO Annual...

gynecologic cancers

MIRASOL Trial: First Targeted Therapy for Platinum-Resistant Ovarian Cancer to Improve Survival Outcomes

Mirvetuximab soravtansine-gynx, a novel antibody-drug conjugate, significantly improved progression-free and overall survival in patients with platinum-resistant, recurrent ovarian cancers that express high levels of folate receptor–alpha (FR-alpha), according to the results of the phase III...

gynecologic cancers

Bobbie J. Rimel, MD, and Kathleen N. Moore, MD, on Ovarian Cancer: New Findings on Mirvetuximab Soravtansine vs Chemotherapy

Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Kathleen N. Moore, MD, of the Stephenson Oklahoma Cancer Center at the University of Oklahoma, discuss phase III results from the MIRASOL trial, which showed that mirvetuximab soravtansine-gynx prolonged overall survival vs investigator’s...

gynecologic cancers
immunotherapy

Mirvetuximab Soravtansine Improves Survival in Patients With Recurrent Ovarian Cancer

The international phase III MIRASOL randomized clinical trial found that mirvetuximab soravtansine-gynx, an antibody and microtubule inhibitor conjugate, significantly improved progression-free and overall survival for patients with platinum-resistant, advanced high-grade epithelial ovarian,...

gynecologic cancers

Simple Hysterectomy May Be a Safe Option for Patients With Early-Stage, Low-Risk Cervical Cancer

Simple hysterectomy with pelvic lymph node dissection may be a safe treatment option for patients with early-stage, low-risk cervical cancer and may help improve quality of life, according to results from the large, international phase III SHAPE clinical trial. The research was presented by Plante...

Expert Point of View: Kathleen Moore, MD, MS

Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, spoke with The ASCO Post about GOG-258. According to Dr. Moore, the final results of this long-running...

gynecologic cancers

ARTISTRY-7 and ROSELLA: Phase III Trials to Evaluate Novel Agents in Platinum-Resistant Ovarian Cancer

Platinum resistance occurs in almost all patients whose ovarian cancer recurs. Single-agent chemotherapies are commonly used in this setting, but outcomes are generally poor, leaving a large unmet need for effective treatment. At the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on...

Expert Point of View: Kathleen Moore, MD, MS

“I think the NOW trial is a great study,” said Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Oklahoma City, who shared her thoughts on the trial with...

Expert Point of View: Kathleen Moore, MD, MS

Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, spoke with The ASCO Post about GOG-258. According to Dr. Moore, the final results of this long-running...

Robin Zon Elected ASCO President for 2024–2025 Term; Other Leadership Positions Filled

ASCO has elected Robin Zon, MD, FACP, FASCO, a long-time member and volunteer, as its President beginning in June 2024. Dr. Zon will take office as President-Elect immediately following the ASCO Annual Business Meeting in Chicago on June 5, 2023. Five additional members were elected to the ASCO...

Robin Zon, MD, FACP, FASCO, Elected ASCO President for 2024–2025 Term

ASCO has elected Robin Zon, MD, FACP, FASCO, a long-time member and volunteer, to lead as its President beginning in June 2024. Dr. Zon will take office as President-Elect immediately following the ASCO Annual Business Meeting in Chicago on June 5, 2023. Five additional members were also elected to ...

ASCO Announces Election Candidates, Voting Opens on November 2

The ASCO Nominating Committee has selected 11 distinguished members as candidates for open leadership positions within the Society. Voting members are urged to vote in the election beginning November 2, 2022. Voting will close on December 6, 2022. President-Elect (4-year term) Robin Zon, MD, FACP, ...

gynecologic cancers

ARIEL4 Confirms Rucaparib’s Efficacy in Recurrent, BRCA-Mutated Ovarian Cancer: Does It Tell Us Anything New?

In March 2022, Kristeleit et al reported the results of the ARIEL4 trial1 of rucaparib in relapsed BRCA-mutant ovarian cancer in The Lancet Oncology (summarized in this issue of The ASCO Post) and are to be congratulated on this accomplishment. This report, along with the almost simultaneous...

gynecologic cancers

Navicixizumab Plus Paclitaxel in Platinum-Resistant Ovarian Cancer

In a phase Ib study reported in the Journal of Clinical Oncology, Fu et al found that the combination of navicixizumab (a bispecific antiangiogenic antibody to VEGF and delta-like ligand 4) and paclitaxel showed activity in patients with platinum-resistant ovarian cancer. Delta-like ligand 4 is a...

gynecologic cancers

IMagyn050 Trial: Addition of Atezolizumab to Bevacizumab and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer

As reported in the Journal of Clinical Oncology by Kathleen N. Moore, MD, and colleagues,1 the phase III IMagyn050/GOG 3015/ENGOT-OV39 trial has shown that the addition of atezolizumab to bevacizumab and chemotherapy did not significantly improve progression-free survival in patients with newly...

gynecologic cancers
immunotherapy

IMagyn050 Trial: Addition of Atezolizumab to Bevacizumab and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer

As reported in the Journal of Clinical Oncology by Kathleen N. Moore, MD, and colleagues, the phase III IMagyn050/GOG 3015/ENGOT-OV39 trial has shown that the addition of atezolizumab to bevacizumab and chemotherapy did not significantly improve progression-free survival in patients with newly...

Expert Point of View: Kathleen N. Moore, MD

Kathleen N. Moore, MD, Associate Professor of Gynecologic Oncology and Director of the Oklahoma TSET Phase I Clinical Trials Program, Stephenson Cancer Center, Oklahoma City, underscored the importance of studying patients with stable disease and less robust partial response, not just those with...

gynecologic cancers

SGO 2020: Updated Analysis of VELIA Trial Shows Antitumor Activity in Ovarian Cancer, but Is It Enough?

An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib and platinum chemotherapy in the...

gynecologic cancers

Expert Point of View: Kathleen N. Moore, MD

Kathleen N. Moore, MD, Associate Professor of Gynecologic Oncology and Director of the Oklahoma TSET Phase I Clinical Trials Program, Stephenson Cancer Center, Oklahoma City, underscored the importance of studying patients with stable disease and less robust partial response, not just those with...

gynecologic cancers

Veliparib Plus Chemotherapy Shows Antitumor Activity in Front-Line Treatment of Ovarian Cancer, but Is It Enough?

An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib and platinum chemotherapy in the...

gynecologic cancers

Expert Point of View: Thomas J. Herzog, MD, and Kathleen N. Moore, MD

Thomas J. Herzog, MD, Deputy Director, University of Cincinnati Cancer Center, who presented a distillation of the PAOLA-1 trial findings along with updated results of the PRIMA trial, called the difference in progression-free survival with the addition of olaparib to bevacizumab “remarkable” after ...

gynecologic cancers

Niraparib in Late-Line Treatment of Ovarian Cancer

In the phase II QUADRA trial reported in The Lancet Oncology, Moore et al found that the poly(ADP-ribose) polymerase (PARP) inhibitor niraparib was active in fourth- or later-line treatment of ovarian cancer, particularly in patients with homologous recombination deficiency (HRD)-positive,...

gynecologic cancers

Results Reported for Olaparib Maintenance in Ovarian Cancer

TWO-YEAR MAINTENANCE therapy with olaparib (Lynparza), a poly (ADP-ribose) polymerase inhibitor, achieved a significant improvement in progression-free survival in patients with newly diagnosed advanced ovarian cancer and a BRCA1 or BRCA2 mutation, according to results of the phase III SOLO-1...

gynecologic cancers

ESMO 2018: SOLO-1: Olaparib Maintenance Extends Progression-Free Survival in BRCA1/2-Mutated Advanced Ovarian Cancer

Two-year maintenance therapy with olaparib (Lynparza), a poly ADP-ribose polymerase (PARP) inhibitor, led to a substantial improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1/2 mutation, results from the phase III SOLO-1 trial...

gynecologic cancers

Kathleen N. Moore, MD, on Ovarian Cancer: Results From the QUADRA Study

Kathleen N. Moore, MD, of the University of Oklahoma Health Sciences Center, discusses phase II study findings on niraparib in patients with relapsed ovarian cancer who have received three or more prior chemotherapy regimens (Abstract 5514).

Conquer Cancer 2018 Awards Presented at ASCO Annual Meeting

The Conquer Cancer Foundation of the ASCO recently announced the recipients of its 2018 ASCO Annual Meeting Merit Awards, Medical Student Rotations for Underrepresented Populations (MSR), Resident Travel Awards for Underrepresented Populations (RTA), and Long-term International Fellowship (LIFe)....

Conquer Cancer Foundation Recognizes 70 Young Oncology Researchers’ Findings With Merit Awards

ASCO’s Conquer Cancer Foundation is pleased to announce the recipients of its Merit Awards in gastrointestinal cancers, clinical immuno-oncology, genitourinary cancers, and cancer survivorship. The following 70 researchers— oncology fellows and trainees honored for the quality and scientific merit...

gynecologic cancers

Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer

Kathleen N. Moore, MD, of Stephenson Cancer Center, The University of Oklahoma, and colleagues found that mirvetuximab soravtansine (also known as IMGN853)—an antibody-drug conjugate targeting folate receptor alpha (FRα)—is active in FRα-positive platinum-resistant ovarian cancer, according to a...

gynecologic cancers

Is Mirvetuximab Soravtansine Active in Platinum-Resistant Ovarian Cancer?

Moore et al found that mirvetuximab soravtansine (also known as IMGN853)—an antibody-drug conjugate targeting folate receptor alpha (FRα)—is active in FRα-positive platinum-resistant ovarian cancer, according to a phase I expansion cohort study reported in the Journal of...

gynecologic cancers

Expert Point of View: Kathleen Moore, MD

Session moderator Kathleen Moore, MD, Associate Professor of Obstetrics and Gynecology at the University of Oklahoma College of Medicine, Oklahoma City, said that while the response rates are “not incredibly high,” trabectedin offers another line of therapy where there previously was none. “I think ...

gynecologic cancers

Pretreatment Lymph Node Dissection May Improve Survival in Advanced Cervical Cancer, But for Too Few? 

Women with cervical cancer metastasized to para-aortic lymph nodes have historically had a poor prognosis, with 3-year overall survival rates of 25% to 40%.1-3 This has been attributed to the presence of occult systemic disease at the time of presentation and a high rate of distant recurrences...

supportive care
survivorship

Maximizing the Benefits of Exercise in Patients With Cancer

Many nonpharmacologic therapies increase both physical and emotional strength during cancer treatment as well as throughout survivorship. These therapies include the mind-body practices of meditation, self-hypnosis, guided imagery, and breath awareness, touch therapies including massage and...

gynecologic cancers
gynecologic cancers

ASCO 2015: IMGN853 Demonstrates Single-Agent Activity for Patients With Platinum-Resistant Ovarian Cancer

In a phase I trial, the investigational agent mirvetuximab soravtansine (IMGN853) was found to be active in patients with platinum-resistant ovarian cancer. ImmunoGen, Inc, announced the first clinical findings of this folate-receptor alpha (FRα)-targeting antibody-drug conjugate at the...

Advertisement

Advertisement




Advertisement